The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells

Megan M. Duckett, Shee Kwan Phung, Linh Nguyen, Ali Khammanivong, Erin Dickerson, Kathryn Dusenbery, Jessica Lawrence

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Adrenergic receptor (AR) expression has been demonstrated at several sites of primary and metastatic tumour growth and may influence proliferation, survival, metastasis and angiogenesis. AR antagonists like propranolol and carvedilol inhibit proliferation, induce apoptosis and synergize with chemotherapy agents in some cancers. Radiation resistance is mediated in many cells by upregulation of pro-survival pathways, which may be influenced by ARs. Studies evaluating AR antagonists combined with radiation are limited. The purpose of this study was to determine the effect of propranolol and carvedilol on viability and radiosensitivity in sarcoma cell lines. The hypothesis was that propranolol and carvedilol would increase radiosensitivity in four primary bone sarcoma cell lines. Single agent propranolol or carvedilol inhibited cell viability in all cell lines in a concentration-dependent manner. The mean inhibitory concentrations (IC50) for carvedilol were approximately 4-fold lower than propranolol and may be clinically relevant in vivo. Immunoblot analysis confirmed AR expression in both human and canine sarcoma cell lines; however, there was no correlation between baseline AR protein expression and radiosensitivity. Short duration treatment with carvedilol and propranolol did not significantly affect clonogenic survival. Prolonged exposure to propranolol and carvedilol significantly decreased the surviving fraction of canine osteosarcoma cells after 3Gy radiation. Based on our results and possible in vivo activity in dogs, further studies investigating the effects of carvedilol on sarcoma are warranted.

Original languageEnglish (US)
Pages (from-to)128-140
Number of pages13
JournalVeterinary and Comparative Oncology
Volume18
Issue number1
DOIs
StatePublished - Mar 1 2020

Bibliographical note

Funding Information:
This study was funded by the Karen Wyckoff Rein in Sarcoma Foundation and the University of Minnesota College of Veterinary Medicine Small Companion Animal Grant Fund. The authors wish to acknowledge Dr. Jaime Modiano (Department of Veterinary Clinical Sciences) for his kind donation of OSCA32 and OSCA40 cells, and both Dr. Modiano and Dr. David R. Brown (Department of Veterinary and Biomedical Sciences) for their assistance in the preparation of this manuscript.

Funding Information:
This study was funded by the Karen Wyckoff Rein in Sarcoma Foundation and the University of Minnesota College of Veterinary Medicine Small Companion Animal Grant Fund. The authors wish to acknowledge Dr. Jaime Modiano (Department of Veterinary Clinical Sciences) for his kind donation of OSCA32 and OSCA40 cells, and both Dr. Modiano and Dr. David R. Brown (Department of Veterinary and Biomedical Sciences) for their assistance in the preparation of this manuscript.

Publisher Copyright:
© 2019 John Wiley & Sons Ltd

Keywords

  • cancer
  • carvedilol
  • cell survival
  • dogs
  • propranolol
  • radiation

PubMed: MeSH publication types

  • Comparative Study
  • Journal Article

Fingerprint

Dive into the research topics of 'The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells'. Together they form a unique fingerprint.

Cite this